|By PR Newswire||
|August 14, 2014 02:11 PM EDT||
GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.
In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been granted certain rights to deploy lentiviral technology in specified therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier. These rights include specified CAR T-cell based therapies as well as specified therapies for single-gene diseases and disorders.
Chimeric antigen receptor T cell therapy (CAR+ T) technologies have made significant advances during the past several years, as evidenced by consistent clinical results reported by several academic teams. "We are pleased that Lentigen Corporation has been at the forefront of the lentiviral vector manufacturing innovation that has enabled these advances in the treatment of hematologic malignancies," said David Wetherell, Chairman of Lentigen Corporation. He added, "this transaction will provide Opus Bio with ongoing access to innovations in lentiviral vector and cell processing technologies, while allowing the company to commit further resources toward the advancement its research and clinical development programs."
Opus Bio intends to make further announcements on the progress of its therapeutic pipeline during the coming months.
Opus Bio is a clinical-stage biotechnology company committed to developing potentially transformative cell therapies for cancer and single gene disorders. The company is backed by Biomark Capital, a life sciences and healthcare investment firm with offices in Greenwich, CT and San Francisco, CA.
Investor and media contact:
Douglas D. Lind, MD
Interim Chief Executive Officer
Opus Bio, Inc.
SOURCE Opus Bio, Inc.
Oct. 22, 2016 07:00 AM EDT Reads: 3,481
Oct. 22, 2016 07:00 AM EDT Reads: 2,251
Oct. 22, 2016 06:45 AM EDT Reads: 352
Oct. 22, 2016 06:30 AM EDT Reads: 2,180
Oct. 22, 2016 06:15 AM EDT Reads: 11,202
Oct. 22, 2016 06:00 AM EDT Reads: 1,341
Oct. 22, 2016 05:45 AM EDT Reads: 16,253
Oct. 22, 2016 05:45 AM EDT Reads: 447
Oct. 22, 2016 05:00 AM EDT Reads: 2,472
Oct. 22, 2016 05:00 AM EDT Reads: 685
Oct. 22, 2016 04:30 AM EDT Reads: 803
Oct. 22, 2016 03:30 AM EDT Reads: 1,664
Oct. 22, 2016 02:45 AM EDT Reads: 1,152
SYS-CON Events announced today that Interface Masters Technologies, a leader in Network Visibility and Uptime Solutions, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Interface Masters Technologies is a leading vendor in the network monitoring and high speed networking markets. Based in the heart of Silicon Valley, Interface Masters' expertise lies in Gigabit, 10 Gigabit and 40 Gigabit Eth...
Oct. 22, 2016 02:45 AM EDT Reads: 3,289
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his session at @DevOpsSummit 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will show how customers are able to achieve a level of transparency that enables everyon...
Oct. 22, 2016 02:45 AM EDT Reads: 1,251